vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Silexion Therapeutics Corp (SLXN). Click either name above to swap in a different company.
Aligos Therapeutics, Inc. is the larger business by last-quarter revenue ($169.0K vs $70.0K, roughly 2.4× Silexion Therapeutics Corp).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Silexion Therapeutics Corp is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and immunological diseases. It serves North American and global healthcare markets, with R&D focused on novel biologic candidates addressing unmet patient medical needs.
ALGS vs SLXN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $70.0K |
| Net Profit | — | $-4.4M |
| Gross Margin | — | — |
| Operating Margin | — | -6294.3% |
| Net Margin | — | -6302.9% |
| Revenue YoY | -72.1% | — |
| Net Profit YoY | 75.8% | — |
| EPS (diluted) | — | $1.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $70.0K | ||
| Q3 25 | $741.0K | $39.0K | ||
| Q2 25 | $965.0K | $44.0K | ||
| Q1 25 | $311.0K | — | ||
| Q4 24 | $606.0K | — | ||
| Q3 24 | $1.3M | $0 | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $694.0K | — |
| Q4 25 | — | $-4.4M | ||
| Q3 25 | $-31.5M | $-3.3M | ||
| Q2 25 | $-15.9M | $-2.5M | ||
| Q1 25 | $43.1M | — | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | $-11.9M | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $-34.9M | — |
| Q4 25 | — | -6294.3% | ||
| Q3 25 | -3827.4% | -8441.0% | ||
| Q2 25 | -1924.0% | -5190.9% | ||
| Q1 25 | -6187.5% | — | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | — | ||
| Q2 24 | -2489.5% | — | ||
| Q1 24 | -3176.7% | — |
| Q4 25 | — | -6302.9% | ||
| Q3 25 | -4256.0% | -8364.1% | ||
| Q2 25 | -1643.8% | -5688.6% | ||
| Q1 25 | 13854.7% | — | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | — | ||
| Q2 24 | 477.0% | — | ||
| Q1 24 | -5023.5% | — |
| Q4 25 | — | $1.50 | ||
| Q3 25 | $-3.04 | $2.88 | ||
| Q2 25 | $-1.53 | $4.32 | ||
| Q1 25 | $-2.11 | — | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | $274.25 | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $2.6M |
| Total Assets | $88.5M | $7.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $6.0M | ||
| Q3 25 | $99.1M | $9.2M | ||
| Q2 25 | $122.9M | $3.5M | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | $2.0M | ||
| Q2 24 | $94.5M | — | ||
| Q1 24 | $112.7M | — |
| Q4 25 | $53.5M | $2.6M | ||
| Q3 25 | $71.8M | $7.0M | ||
| Q2 25 | $101.9M | $120.0K | ||
| Q1 25 | $116.4M | — | ||
| Q4 24 | $-29.0M | — | ||
| Q3 24 | $50.1M | $-4.6M | ||
| Q2 24 | $67.2M | — | ||
| Q1 24 | $59.8M | — |
| Q4 25 | $88.5M | $7.2M | ||
| Q3 25 | $109.8M | $11.6M | ||
| Q2 25 | $134.7M | $5.8M | ||
| Q1 25 | $150.7M | — | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $88.4M | $3.1M | ||
| Q2 24 | $108.8M | — | ||
| Q1 24 | $127.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-3.0M |
| Free Cash FlowOCF − Capex | — | $-3.0M |
| FCF MarginFCF / Revenue | — | -4311.4% |
| Capex IntensityCapex / Revenue | — | 2.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-3.0M | ||
| Q3 25 | $-24.3M | $-2.8M | ||
| Q2 25 | $-15.5M | $-2.5M | ||
| Q1 25 | $-20.9M | — | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-20.1M | $-2.7M | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-22.7M | — |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-2.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -4311.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5700.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 2.9% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
